UK Modern Slavery Statement 2022
Pursuant to section 54(1) of the UK Modern Slavery Act for the financial year ending on
31 December 2022, the following describes new and ongoing steps Moderna is taking toprevent modern slavery and protect human rights within our business and our supply
chains.

Our Company
Moderna is using nature's information molecule, messenger RNA (mRNA), to reimagine
how medicines are made and to transform how we treat and prevent disease foreveryone. Through more than a decade of investment in science, Moderna has been aleader in the creation of the field of mRNA medicine since its founding in 2010. Working
at the intersection of science, technology and health, the company has developed
medicines at unprecedented speed and efficiency, including one of the earliest andmost effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines
for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, andautoimmune diseases. With a unique culture and a global team driven by the Modernavalues and mindsets to responsibly change the future of human health, Moderna strives
to deliver the greatest possible impact to people through mRNA medicines.
By the end of 2022, we had approximately 3,900 full-time employees in 17 locations acrossNorth America, the United Kingdom, Europe, and Asia Pacific, including 27 employees inthe United Kingdom.
In December 2022, Moderna and the UK Government announced the finalization of aten-year strategic partnership to establish a state-of-the-art mRNA research,development, and manufacturing facility in the UK. Construction commenced on theModerna Innovation and Technology Centre in Oxfordshire in April 2023.

Our Human Resources PracticesModerna is committed to creating and ensuring a non-discriminatory and respectful
working environment for all its employees worldwide. Moderna recruitment and HumanResources practices are designed to help ensure that all prospective employees arelegally entitled to work in the country in which they reside and to help safeguard
employees from any abuse or coercion once in our employment.

Our Supply Chain
Moderna’s supply chain is comprised of suppliers of goods and services: (i) tomanufacture, store, and distribute our vaccine, such as raw materials, drug substance,drug products, testing, fill-finish services, warehousing, and transportation; (ii) for our
research and development activities, such as clinical research organizations,laboratories, equipment, and supplies; and (iii) to run our business, such as information
technology, professional services, sales and marketing, and facilities.

Our Policies in relation to Slavery and Human Trafficking
Moderna has policies in place which aim to minimize the risk of modern slavery or humantrafficking and encourage reporting of any related concerns.
The Code of Business Conduct and Ethics establishes the minimum standards that areexpected from all our employees when conducting business and their day-to-dayactivities. All directors, officers, and employees are expected to review the Code andacknowledge their understanding on a periodic basis.
The Human Rights Policy establishes the obligation of Moderna personnel to protect
human rights and report any concerns they may identify in the course of their work
responsibilities, including those that may occur in a Moderna service provider or supplier.
Our employees must read and acknowledge the Human Rights Policy during their
onboarding process.
The Speak Up Hotline empowers Moderna’s employees and third parties to submit
questions or voice concerns about inappropriate, unethical, or illegal behavior. This
includes any allegations of modern slavery against our suppliers. Both employees andthird parties may choose to submit reports anonymously, where permitted by law.
Concerns can be made by via email, phone, online or in-person. The web-based andtelephone channels are operated via a third-party vendor. Reports made via the Speak
Up hotline are addressed on a case-by-case basis. Moderna prohibits any form ofretaliation or intimidation for reports made in good faith. Concerns are investigated andacted on as required.
The Third-Party Code of Business Conduct reinforces Moderna’s standards andexpectations of our contractual business partners. We strive to work with partners whobring value to Moderna and align with our high ethical standards and values.

Our Key Activities in the past 12 months
During the past 12 months, Moderna:
Has not received any reports from employees, the public, or law enforcement
agencies to indicate that modern slavery practices have been identified, either
at Moderna or in its supply chain.

Launched Moderna’s re-imagined Code of Ethics and Business Conduct as aprinciples-based approach.



Launched Moderna’s Third Party Code of Business Conduct.

The Speak Up Hotline is enabled to receive reports in all the languages spoken atModerna affiliates worldwide and incorporate a telephone number for Latin
America and Asia Pacific.

Implemented Moderna’s Cross-Functional Due Diligence Program that assesses
several aspects including the reputation and ethical behaviour of applicable thirdparties. The implementation of this Program included:

Moderna’s Procurement organization implemented the due diligencequestionnaire for key and high-risk suppliers. The questionnaire requires thirdparties to provide information about their policies on human rights, and workplace
conditions to provide assurance these are consistent with our standards.
Our Ethics & Compliance due diligence process obtains additional informationfrom an external third party on high-risk key suppliers. This due diligence processincludes a specific section on Human Rights, Modern Slavery and Employmentpractices.

To continue ongoing due diligence and monitoring, Moderna’s Procurement
organization implemented the EcoVadis solution to assess supplier’s ESG
performance on four key themes: Environment, Labor & Human Rights, Ethics, andSustainable Procurement. The Labor & Human Rights theme covers criteria
surrounding child labor, forced labor, discrimination, harassment, working
conditions, human trafficking, and debt bondage. The EcoVadis solution enables
Moderna to identify inherent modern slavery risks within the supply chain, assess
specific supplier risk areas, verify the validity of supplier responses, and identify
opportunities for corrective actions.

Our Commitment for the next 12 months
Moderna understands that tackling modern slavery requires a continuing year-over-year
commitment and will continue to conduct due diligence of our supply chain as well as
review and improve procedures to help identify and prevent the risks of modern slavery
or human trafficking. During the next 12 months, Moderna plans to:Improve the awareness of the UK Modern Slavery Act (2015) by including
information during onboarding programs and inform new hires of the appropriate
action to take if they suspect a case of slavery or human trafficking.

Launch internal campaign to promote awareness of the UK Modern Slavery Act
and Moderna’s commitment to Human Rights and the reporting mechanisms toraise such concerns.

Definition of Key Performance Indicators-Number of concerns or reports received through the Speak Up Hotline
related to violations of the UK Modern Slavery Act or any other HumanRights violation.

-Number of vendors identified through our due diligence process thathave past records of violations of the UK Modern Slavery Act or anyother Human Rights.

This statement has been approved by the board of directors of Moderna Biotech UKLimited.

Brian Sandstrom
Brian Sandstrom, Director of Moderna Biotech UK Limited
Date: October 2023